Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211048) titled 'Anti CD19 Gene Therapy for B-cell Lymphoma' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Anhui Provincial Hospital

Condition: B-cell Lymphoma

Intervention: Drug: Anti-CD19 gene injection

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: October 20, 2025

Target Sample Size: 18

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07211048

Published by HT Digital Content Services with permission from Health Dail...